Frequency of in vitro resistance of Pseudomonas aeruginosa to cefepime, ceftazidime, and cefotaxime

Keywords

Cefepime, Ceftazidime, Cefotaxime, Microbiology, Cephalosporin

References

• Susceptibility to penicillins and cephalosporins in beta-lactamase producing strains of E. coli and relative amount of beta-lactamase produced from these strains.Staffan Normark, Thomas Grundström, Sven Bergström — 1980
• A spectrophotometric assay of beta-lactamase action on penicillins.Stephen G. Waley — 1974
• Evolution of plasmid-coded resistance to broad-spectrum cephalosporinsChristine Kliebe, Berthold Nies, Joachim Meyer — 1985
• A direct spectrophotometric assay and determination of Michaelis constants for the beta-lactamase reaction.Amram Samuni — 1975
• Dissemination of the novel plasmid-mediated beta-lactamase CTX-1, which confers resistance to broad-spectrum cephalosporins, and its inhibition by beta-lactamase inhibitorsM Kitzis, D Billot-Klein, F. W. Goldstein — 1988
• Affinity of cephalosporins for beta-lactamases as a factor in antibacterial efficacyD J Phelps, Donna Carlton, Cathy A. Farrell — 1986
• Novel plasmid-mediated beta-lactamase in clinical isolates of Klebsiella pneumoniae more resistant to ceftazidime than to other broad-spectrum cephalosporinsA Petit, D. Sirot, Corinne Chanal — 1988
• Synergistic resistance mechanisms in Pseudomonas aeruginosa.Charles W. Stratton, Francisca Tausk — 1987
• Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobicallyJ. Allan Waitz — 1990
• Contribution of chromosomal beta-lactamases to beta-lactam resistance in enterobacteria.Frederik P. Lindberg, Staffan Normark — 1986

Cited by

• Preclinical development of Ramizol, an antibiotic belonging to a new class, for the treatment of Clostridium difficile colitis真光 市川, 学柱 夫 — 2016
• Assessment of the Effect of Induced Hypothermia in Experimental Sepsis Using a Cecal Ligation and Perforation Mouse ModelKaren Yao Luo — 2011
• Cefepime: the next generation?Christine C. Sanders — 1993
• Cefepime microbiologic profile and updateR E Kessler — 2001
• A new therapeutic option for the treatment of pneumonia.Robert P. McCabe, Valerie A. Chirurgi, Stephen A. Farkas — 1996
• Future directions in antimicrobial chemotherapyRobert Janknegt — 1992
• Bacteriologic and clinical applications of a new extended-spectrum parenteral cephalosporin.John Segreti, Stuart Levin — 1996
• Cefepime use in a pediatric intensive care unit reduces colonization with resistant bacilliPhilip Toltzis, Michael Dul, Mary Ann O’Riordan — 2003
• Comparative in vitro activity of cefepime (BMY 28142) against multiresistant nosocomial isolates ofPseudomonas aeruginosaD. Voutsinas, Th. Mavroudis, A. Avlamis — 1989
• Advances in the pharmacotherapy of cystic fibrosisJohn A. Bosso — 1992
• Cefepime Clinical PharmacokineticsMark P. Okamoto, Randall K. Nakahiro, Alfred Chin — 1993
• Cefepime versus Ceftazidime for Treatment of PneumoniaΚωνσταντίνος Κωνσταντίνου, Kavitha Baddam, Asela Tharanga Lanka — 2004
• Activity of cefepime against ceftazidime- and cefotaxime-resistant gram-negative bacteria and its relationship to beta-lactamase levelsJ Fung-Tomc, Thomas J. Dougherty, F J DeOrio — 1989
• Pharmacokinetics of cefepime after single and multiple intravenous administrations in healthy subjectsRashmi H. Barbhaiya, S. Thomas Forgue, Carol Gleason — 1992
• Correlation of in vitro and in vivo resistance development to antimicrobial agentsJ Fung-Tomc — 1990
• Susceptibility of bacterial isolates to beta-lactam antibiotics from U.S. clinical trials over a 5-year period.R E Kessler, J Fung-Tomc — 1996
• CefepimeLee B. Barradell, Harriet M. Bryson — 1994
• Antibiogram-derived radial decision trees: Innovative visual educational tools for discussing empirical antibiotic selectionsPaul Belliveau, Rocco J. Perla — 2007
• Cefclidin (E1040), a novel cephalosporin: lack of selection of beta-lactamase overproducing mutants in an in vitro pharmacokinetic model system.Naoaki Watanabe, Kanemasa Katsu — 1992
• Comparative activity of cefepime, alone and in combination, against clinical isolates of Pseudomonas aeruginosa and Pseudomonas cepacia from cystic fibrosis patientsJohn A. Bosso, B A Saxon, John M. Matsen — 1991

Related papers

• COST-EFFECTIVENESS ANALYSIS OF CEFEPIME COMPARED WITH CEFTAZIDIME IN INTENSIVE CARE UNIT PATIENTS WITH HOSPITAL-ACQUIRED PNEUMONIAPaul G. Ambrose, Mark A. Richerson, Mary-Elizabeth Stanton — 1999
• International comparative study of cefepime and ceftazidime in the treatment of serious bacterial infections.A. I. M. Hoepelman, Hans Kieft, Mabel Aoun — 1993
• Cefepime versus ceftazidime for the treatment of serious bacterial infections.Alfredo Ponce‐de‐León, Mauricio López–Meneses, José Sifuentes‐Osornio — 1999
• Cost-effectiveness Analysis of Cefepime and Ceftazidime in Treatment of Bacterial InfectionsWen Leong Yu — 2001
• Cost-effectiveness analysis of cefepime vs ceftazidime in treatment of pneumoniaXiang Li — 2000
• Activity of cefepime against ceftazidime- and cefotaxime-resistant gram-negative bacteria and its relationship to beta-lactamase levelsJ Fung-Tomc, Thomas J. Dougherty, F J DeOrio — 1989
• Development of resistance in Pseudomonas aeruginosa to broad-spectrum cephalosporins via step-wise mutations.Elizabeth Gradelski, J Fung-Tomc, E Huczko — 1993
• Septicaemia caused by an enterobacter cloacae strain varying in resistance against cephalosporinsBjørg Marit Andersen, Inger Marie S. Dahl, R.C. George — 1989